Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

The marketing and supply agreement is for a period of five years for India only, to enhance distribution and in clinic presence of the two products.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. However, even in a bull market, like the one we're currently ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert Bourla, Ph.D., outlined one potential response by his company if ...

Pfizer will end the global commercialisation ... where it was previously known under the brand name Durveqtix. Beqvez was developed in partnership with the now Roche-owned Spark Therapeutics ...

Pfizer Ltd on Friday said its board approved signing a marketing and supply agreement with Mylan Pharmaceuticals Pvt Ltd for two of its brands -- Ativan and Pacitane. Ativan is used for the treatment ...

Pfizer Inc. (NYSE:PFE – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders bought 294,496 call options on the stock. This represents an increase of ...